This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
AOP: 121
Title
Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat)
Short name
Graphical Representation
Point of Contact
Contributors
- Charles Wood
Coaches
OECD Information Table
OECD Project # | OECD Status | Reviewer's Reports | Journal-format Article | OECD iLibrary Published Version |
---|---|---|---|---|
1.29 |
This AOP was last modified on April 29, 2023 16:02
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Increase, Urinary bladder calculi | October 26, 2017 09:27 |
Increase, Cytotoxicity (urothelial cells) | September 16, 2017 10:16 |
Increase, Regenerative cell proliferation (urothelial cells) | September 16, 2017 10:16 |
Increase, Hyperplasia (urothelial) | September 16, 2017 10:16 |
Increase, Adenomas/carcinomas (urothelial) | September 16, 2017 10:16 |
Increase, Urinary bladder calculi leads to Increase, Cytotoxicity (urothelial cells) | December 03, 2016 16:38 |
Increase, Cytotoxicity (urothelial cells) leads to Increase, Regenerative cell proliferation (urothelial cells) | December 03, 2016 16:38 |
Increase, Regenerative cell proliferation (urothelial cells) leads to Increase, Hyperplasia (urothelial) | December 03, 2016 16:38 |
Increase, Hyperplasia (urothelial) leads to Increase, Adenomas/carcinomas (urothelial) | December 03, 2016 16:38 |
Abstract
This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 793 | Increase, Urinary bladder calculi | Increase, Urinary bladder calculi |
KE | 794 | Increase, Cytotoxicity (urothelial cells) | Increase, Cytotoxicity (urothelial cells) |
KE | 795 | Increase, Regenerative cell proliferation (urothelial cells) | Increase, Regenerative cell proliferation (urothelial cells) |
KE | 796 | Increase, Hyperplasia (urothelial) | Increase, Hyperplasia (urothelial) |
AO | 797 | Increase, Adenomas/carcinomas (urothelial) | Increase, Adenomas/carcinomas (urothelial) |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Life Stage Applicability
Taxonomic Applicability
Sex Applicability
Sex | Evidence |
---|---|
Male | |
Female |
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Quantitative Understanding
Considerations for Potential Applications of the AOP (optional)
References
Garland, E. M., & Cohen, S. M. (1995). Saccharin-induced bladder cancer in rats. Prog Clin Biol Res, 391, 237-243.
International Agency for Research on Cancer (IARC), W. H. O. (1999). Saccharin and its Salts, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (Vol. 73-24). France.